Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lushang Freda Pharmaceutical CoSHSE:600223 68 PS Ratio is 1.57 as of Aug. 07, 2026, which is 67% above its 10-year median of 0.94. GuruFocus rates SHSE:600223 with a GF Score™ of 68/100 and a GF Value™ of ¥6.56 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 1,742 Real Estate companies, Lushang Freda Pharmaceutical Co ranks better than 60.1% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Lushang Freda Pharmaceutical Co's share price is ¥5.49.
Lushang Freda Pharmaceutical Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ¥3.49. Hence, Lushang Freda Pharmaceutical Co's PS Ratio for today is 1.57.
Good Sign:
Lushang Freda Pharmaceutical Co Ltd stock PS Ratio (=1.5) is close to 2-year low of 1.42.
The historical rank and industry rank for Lushang Freda Pharmaceutical Co's PS Ratio or its related term are showing as below:
SHSE:600223'
s PS Ratio Range Over the Past 10 Years
Min: 0.26 Med: 0.94 Max: 2.25
Current: 1.6
During the past 13 years, Lushang Freda Pharmaceutical Co's highest PS Ratio was 2.25. The lowest was 0.26. And the median was 0.94.
SHSE:600223's PS Ratio is ranked better than 60.1% of 1742
companies
in the Real Estate industry
Industry Median: 2.38
vs SHSE:600223: 1.60
During the past 13 years, Lushang Freda Pharmaceutical Co's highest 3-Year average Revenue per Share Growth Rate was 53.50% per year. The lowest was -32.50% per year. And the median was 13.75% per year.
Lushang Freda Pharmaceutical Co (SHSE:600223) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Lushang Freda Pharmaceutical Co PS Ratio Related Terms
Lushang Freda Pharmaceutical Co PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lushang Freda Pharmaceutical Co PS Ratio Competitor Comparison
For the Real Estate - Development subindustry, Lushang Freda Pharmaceutical Co's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lushang Freda Pharmaceutical Co PS Ratio vs Real Estate Industry
For the Real Estate industry and Real Estate sector, Lushang Freda Pharmaceutical Co's PS Ratio distribution charts can be found below:
* The bar in red indicates where Lushang Freda Pharmaceutical Co's PS Ratio falls into.
Lushang Freda Pharmaceutical Co PS Ratio Calculation
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Lushang Freda Pharmaceutical Co's Share Price of today is ¥5.49. Lushang Freda Pharmaceutical Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥3.49.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Lushang Freda Pharmaceutical Co (SHSE:600223) has a PS Ratio of 1.57 as of Aug. 07, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Lushang Freda Pharmaceutical Co and its competitors. This is 67% above median its historical median of 0.94. Over the past decade, Lushang Freda Pharmaceutical Co's PS Ratio has ranged from 0.26 to 2.25. According to the industry distribution chart, Lushang Freda Pharmaceutical Co ranks #695 out of 1742 companies in the Real Estate industry, placing it in the top 39.9%.
Is Lushang Freda Pharmaceutical Co's PS Ratio too high?
Lushang Freda Pharmaceutical Co's current PS Ratio of 1.57 is 67% above median its 10-year median of 0.94. Over the past 10 years, this metric has ranged from a low of 0.26 to a high of 2.25. The Real Estate industry median PS Ratio is 2.38. Lushang Freda Pharmaceutical Co's value of 1.57 is 34% below this industry median. Based on the distribution chart, Lushang Freda Pharmaceutical Co ranks #695 out of 1742 companies in the Real Estate industry, which is above the industry midpoint. Overall, Lushang Freda Pharmaceutical Co has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lushang Freda Pharmaceutical Co's PS Ratio compare to competitors?
According to the Real Estate industry distribution chart, Lushang Freda Pharmaceutical Co ranks #695 out of 1742 companies for PS Ratio. This puts Lushang Freda Pharmaceutical Co in the upper half of its industry. The industry median PS Ratio is 2.38. Lushang Freda Pharmaceutical Co's value of 1.57 is 34% below this benchmark. Historically, Lushang Freda Pharmaceutical Co's own PS Ratio has ranged from 0.26 to 2.25 over the past decade. While the company's 10-year median is 0.94 vs. the industry median of 2.38, Lushang Freda Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Real Estate company?
The median PS Ratio among Real Estate companies is 2.38, based on 1,742 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lushang Freda Pharmaceutical Co's current PS Ratio of 1.57 is 34% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Lushang Freda Pharmaceutical Co and its competitors. For the Real Estate industry, the median PS Ratio is 2.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lushang Freda Pharmaceutical Co's current PS Ratio is 1.57, which is 67% above median its own 10-year median of 0.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lushang Freda Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Lushang Freda Pharmaceutical Co (SHSE:600223) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥6.56, compared to a current price of ¥5.49 — trading 16.3% below its estimated fair value. The current PS Ratio is 1.57, which is 67% above median its 10-year median of 0.94 and 34% below the Real Estate industry median of 2.38. Lushang Freda Pharmaceutical Co's overall GF Score™ is 68/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Lushang Freda Pharmaceutical Co (SHSE:600223), the current PS Ratio is 1.57 as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lushang Freda Pharmaceutical Co (SHSE:600223) Overvalued in 2026?
Based on GuruFocus' analysis, Lushang Freda Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥5.49 is trading 16.3% below its estimated GF Value™ of ¥6.56.
GuruFocus considers Lushang Freda Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for SHSE:600223:
PS Ratio: 1.57 (67% above median its 10-year median of 0.94)
GF Value™: ¥6.56 vs. price of ¥5.49 (16.3% below fair value)
Industry Position: 34% below the Real Estate median (#695 of 1742)
No single metric tells the full story. See the SHSE:600223 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lushang Freda Pharmaceutical Co Ltd formerly Lushang Health Industry Development Co Ltd is a real estate developer in China. The company is engaged in the development of office buildings, infrastructure, apartments, and hotels.
68GF Score
Get the complete analysis for SHSE:600223
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600223 has been successfully added to your 
